Molecular response to IFN or IM treatment and probability of TFR 3 years after stopping IM
| . | . | . | Proportion of patients in TFR . | . | |
|---|---|---|---|---|---|
| Median . | Range . | <Median . | >Median . | P . | |
| IFN-IM cohort | |||||
| BCR-ABL% at IM start (n = 16) | 0.76 | 0-86 | 0.600 | 0.500 | .48 |
| Days to MR4.0 (n = 18) | 258 | 78-1199 | 0.667 | 0.444 | .27 |
| Days to first UMRD (n = 17) | 244 | 89-1841 | 0.750 | 0.333 | .04 |
| IM-only cohort | |||||
| Days to MMR (n = 16) | 177 | 80-495 | 0.469 | 0.375 | .46 |
| Days to MR4.0 (n = 17) | 427 | 160-1209 | 0.375 | 0.444 | .95 |
| Days to first UMRD (n = 17) | 475 | 160-1608 | 0.429 | 0.400 | .53 |
| . | . | . | Proportion of patients in TFR . | . | |
|---|---|---|---|---|---|
| Median . | Range . | <Median . | >Median . | P . | |
| IFN-IM cohort | |||||
| BCR-ABL% at IM start (n = 16) | 0.76 | 0-86 | 0.600 | 0.500 | .48 |
| Days to MR4.0 (n = 18) | 258 | 78-1199 | 0.667 | 0.444 | .27 |
| Days to first UMRD (n = 17) | 244 | 89-1841 | 0.750 | 0.333 | .04 |
| IM-only cohort | |||||
| Days to MMR (n = 16) | 177 | 80-495 | 0.469 | 0.375 | .46 |
| Days to MR4.0 (n = 17) | 427 | 160-1209 | 0.375 | 0.444 | .95 |
| Days to first UMRD (n = 17) | 475 | 160-1608 | 0.429 | 0.400 | .53 |